This increased capacity of LPL to produce IL-17A in treatment-resistant RCDII may be related to the continued inflammation and risk of EATL development, as IL-17A is involved in chronic inflammation as well as in tumour formation [31]. Here, LPL is linked to enteropathy-associated T-cell lymphoma.